[Pharmacoeconomics and outcome research on Irritable Bowel Syndrome review of findings using Tegaserod]. / Farmacoeconomía e investigación de resultados en el Síndrome de Intestino Irritable: revisión de la evidencia con Tegaserod.

Irritable Bowel Syndrome (IBS) is a chronic and episodic disease that affects 14.5% of females in the United States, and its impact decreases the quality of life. On the other hand, IBS consumes a great part of the health budget and develops indirect costs by loss of work productivity. Currently Tagaserod an agonist of the number 4 serotonin receptors (5-HT4), indicated for IBS-Constipation treatment, has demonstrated savings while optimizing health resources and improving the quality of life of patients and their work productivity.